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(1) The AMP-activated protein kinase (AMPK) is an evolutionary conserved serine/threonine 
protein kinase that functions as a major regulator of cellular and whole-body energy 
homeostasis coordinating multiple metabolic pathways to adapt cellular processes to the 
energy status. AMPK is an heterotrimeric complex composed of one catalytic () and 
two regulatory subunits ( and ). AMPK activation requires phosphorylation on Thr172 
within the activation loop of the catalytic -subunit by upstream kinase, identified as the 
liver kinase B1 (LKB1). 
 
(2) AMPK is activated in response to a variety of physiological processes and pathological 
stresses that typically change the cellular AMP/ATP ratio caused by increasing ATP 
consumption or reducing ATP production. Activated AMPK switches cells from an 
anabolic to a catabolic state, shutting down the ATP-consuming synthetic pathways and 
initiating ATP-producing pathway to restore energy balance. In addition, adipokines such 
as adiponectin and resistin, that regulates whole-body energy balance, may also affect 
hepatic AMPK activity and could contribute to the fed-to-fasted transition from 
anabolism to catabolism in the liver [1]. 
 
(3) As well as responding to metabolic stresses, AMPK is activated by various 
pharmacological and phytochemical products including the antidiabetic drug metformin, 
AICAR and resveratrol. Recent evidence confirms that these compounds behave as 
indirect AMPK activators by causing a mild impairment of ATP synthesis [2-4]. 
Intriguingly, AMPK is dispensable for the effects of metformin and AICAR on hepatic 
gluconeogenesis, acting directly by reducing energy charge through inhibition of the 
respiratory-chain complex I [2, 3]. 
 
(4) AMPK controls the fate of fatty acids by reducing intracellular malonyl-CoA content 
which is both a critical precursor for biosynthesis of fatty acids and a potent inhibitor of 
mitochondrial fatty acid oxidation via the allosteric regulation of carnitine 
palmitoyltransferase 1 (CPT1) which catalyzes the entry of long-chain fatty acyl-CoA 
into mitochondria. AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC) 
and increases malonyl-CoA decarboxylase (MCD) activity resulting in lower malonyl-
CoA levels and therefore promoting mitochondrial -oxidation while simultaneously 
suppressing fatty acid synthesis. The activity of glycerol-3-phosphate acyltransferase 
(GPAT), the first committed step in triacylglycerol synthesis, is also regulated by AMPK 
activation. The cholesterol biosynthesis is controlled by AMPK through direct 
phosphorylation and inhibition of the rate limiting enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase [1]. 
 
(5) Although the action of AMPK is achieved by rapid and direct phosphorylation of key 
metabolic enzymes, long-term effects have been clearly demonstrated on the expression 
of a number of gene sets. AMPK promotes the induction of the transcriptional 
mitochondrial gene program and the inhibition of lipogenesis gene expression by direct 
phosphorylation of transcription factors and co-activators [1, 3, 5]. Interestingly, AMPK 
influences the NAD
+
-dependent SIRT1 deacetylase activity by modulation of NAD+ 
levels following induction of fatty acid oxidation and thus may indirectly modulate the 
acetylation and activity of certain trancriptional regulators in addition to direct 
phosphorylation events [6]. AMPK phosphorylates the transcriptional coactivator 
peroxisome proliferator-activated receptor- coactivator-1  (PGC-1 ), which controls 
the expression of multiple transcription factors to induce mitochondrial biogenesis, and 
results in greater mitochondrial oxidative capacity by increasing PGC1- expression and 
activation through PGC1- promoter autoregulation and SIRT1-mediated deacetylation, 
respectively [6, 7]. AMPK participates in the regulation of lipogenesis gene expression 
by phosphorylation of the carbohydrate response element binding protein (ChREBP), 
reducing its DNA binding capacity and nuclear translocation, and down-regulating sterol 
regulatory element-binding protein-1c (SREBP-1c) gene expression and stability 
probably through SIRT1-dependent deacetylation [1, 5]. Lastly, the phosphorylation of 
CREB-regulated transcription coactivator 2 (CRTC2) by AMPK promotes CRTC2 
binding to 14-3-3 proteins in the cytoplasm and prevents its translocation to the nucleus, 
thereby reducing CREB-dependent expression of the gluconeogenesis genes [1], although 
this effect was recently challenged [2]. 
 
(6) AMPK activation also inhibits other ATP-consuming anabolic pathways such as protein 
synthesis. This occurs by multiple mechanisms including inhibition of the mTOR/S6K1 
pathway, that stimulates translational initiation, through sequential phosphorylation of the 
TSC2 tumor suppressor by the kinases AMPK and GSK3 as well as AMPK-dependent 
phosphorylation of the critical mTOR-binding subunit raptor [8] and activation of eEF2 
kinase which inhibits the elongation step. 
 
(7) Under nutrient starvation, the liver initiates the process of autophagy (lysosomal 
breakdown of cellular proteins and organelles) to provide amino acids for 
gluconeogenesis. Recent evidence indicates that AMPK is required for autophagy in 
hepatocyte, revealing a direct connection between energy status and autophagy initiation 
[9]. 
 
(8) The mTOR/S6K1 pathway exerts a negative feedback loop on insulin signaling promoting 
insulin resistance via inhibitory serine phosphorylation of
 
IRS1. Pharmacologic 
enhancement of AMPK activity has been shown to improve insulin sensitivity and 
AMPK-induced inhibition of the mTORC1/S6K1
 
pathway may alleviate hepatic insulin 
resistance. Additionally, AMPK activation may also modulate insulin's metabolic action 
by increasing fatty acid oxidation, thereby reducing hepatic lipotoxicity and insulin 
resistance [5, 10]. Therefore, the efficacy of AMPK activation to reverse many metabolic 
disorders has provided the rationale for the development of new pharmacological but also 
nutritional AMPK activators. 
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